Scientific Program

Conference Series Ltd invites all the participants across the globe to attend 8th Euro Biotechnology Congress Frankfurt, Germany.

Day 1 :

Keynote Forum

Manfred T. Reetz

Philipps-University Germany

Keynote: Increasing the Efficiency of Directed Evolution of Enzymes

Time : 10:10-10:40

Conference Series Euro Biotechnology 2015 International Conference Keynote Speaker Manfred T. Reetz photo

Manfred T. Reetz , former Director of the Max-Planck-Institut für Kohlenforschung in Mülheim, is currently emeritus Hans-Meerwein-Research-Professor at the University of Marburg/Germany. During the last 15 years his group has helped to shape the emerging field of directed evolution, especially in the quest to evolve stereoselective enzymes as catalysts in organic chemistry


Since its conception some time ago (M.T. Reetz, et al, Angew. Chem. Int. Ed. Engl. 1997, 36, 2830-2832), the idea of directed evolution of stereoselective enzymes as a new approach to asymmetric catalysis has been generalized by us and other research groups to include essentially all of the known enzyme types, including hydrolases, reductases, oxygenases, transferases, and C-C bond forming enzymes such as aldolases, oxynitrilases and pyruvate decarboxylases. Since the screening step is the bottleneck of this type of Darwinian laboratory evolution, the real challenge is to obtain mutant libraries of highest quality requiring a minimum of screening effort. In this endeavor we have proposed iterative saturation mutagenesis (ISM), which has proven to be an extremely valuable tool. The lecture will focus on the newest methodology developments. Review of ISM: C. G Acevedo-Rocha, S. Kille, M. T. Reetz, Methods in Molecular Biology, Vol. 1179, pp. 103-128, Humana Press, 2014; Perspective article of enzymes as catalysts in organic and pharmaceutical chemistry: M. T. Reetz, J. Am. Chem. Soc. 2013, 135, 12480-12496.

Keynote Forum

W Tim Miller

Echelon Bioscience Inc, USA

Keynote: Trade secrets and laboratory security

Time : 10:40-11:10

Conference Series Euro Biotechnology 2015 International Conference Keynote Speaker W Tim Miller photo

W Tim Miller has been the President/CEO of Echelon-Frontier since early 2002, one of Utah’s leading private biotech companies, directing multiple acquisitions, technology licenses, and product launches targeting pharmaceutical, agricultural, and industrial applications. He is recognized by the USA SBA for job creation and commercialization. His deep experience in building Fortune 500 divisions and successful business start-ups and exits, including IPO, in pharmaceuticals, diagnostics, and medical device markets is noteworthy. He has held many past Senior Management Positions including those at Wyeth, Marion Laboratories, and American Hospital Supply/Baxter. He has an MBA from University of Utah (UU) where he graduated first in class with honors and teaches as an adjunct. He was awarded Utah’s Governor’s Medal for Science and Technology in 2011.


Laboratory security and protection of trade secrets and proprietary company information is becoming more critical as insider, outsider and cyber-attack threats are mounting. Rapid technology advances and more globalized supply chains dramatically increase the threat to sensitive corporate information, data and know-how. Trade secrets protect information. The nature of their secrecy imparts competitive, economic and portfolio value. They may encompass a manufacturing process for example, cell growth conditions or successful cell line characteristics, unique synthesis prep, food or drink recipe, a search algorithm, a lubricant formula or a key supplier or customer list. Once a trade secret is obtained by a competitor or made public, its value is lost and that value may never be recovered. And the US Brookings Institution estimates ‘at least 50% and possibly as much as 85%’ of tech company value is attributable to intangible assets. In 2012, the US National Security agency estimated that US businesses lose $334 billion per year due to trade secret thefts and cyber-breaches, a number that is under-estimated as it does not account for costs businesses absorb to protect their secrets. The US FBI reported that during 2009-2013, theft of trade secret cases increased by more than 60%. The USA passed the Economic Espionage Act of 1996 to protect US companies from misappropriation of trade secrets for economic gain or to benefit foreign governments. The EU is actively involved in evaluating the growing threat of trade secret theft and potential EU response. A survey across EU countries showed that over the past ten years, 20% of the respondents experienced at least one attempt or act of misappropriation with 40% believing the risk has increased. Each EU country has some form of protection and effectiveness across member states but the protection varies. A 2012 EU study, European Commission-Roadmap on the Protection of Trade Secrets, offered a number of suggestions for improving trade secret protection including: Providing consistency as to the types of information that can be protected, Addressing difficulties in obtaining evidence of misuse and damage, Making available effective preliminary and effective final injunctions and Importance of providing for effective civil actions in addition to criminal activities. It was mentioned in the European Commission Study on Trade Secrets and Confidential Business Information in the Internal Market in April 2013 that ‘A consensus among economists has emerged that trade secrets play an important role in protecting the returns to innovation and that trade secret protection is an integral part of the overall system of protection available to EU firms to protect their intangible assets like patents and copyrights’. An actual case study will be presented with security measures implemented post discovery by the US FBI involvement and its judicial outcomes. Actual practices and suggestions will be presented which should be viewed as important investments to preserve and actually enhance value related to intellectual property and trade secrets in biotechnology companies.

Keynote Forum

Wilfried Schwab

Technische Universität München Germany

Keynote: Aroma glucoside production

Time : 11:30-12:00

Conference Series Euro Biotechnology 2015 International Conference Keynote Speaker Wilfried Schwab photo

Prof. Schwab studied food chemistry at the University of Würzburg and did his doctorate in 1989. Following a postdoctoral stay at Washington State University, he spent three years working in Hoechst AG’s agriculture division. He returned to the University of Würzburg to complete his lecturer qualification in 1999. He worked in research after that, notably at Plant Research International in Wageningen (the Netherlands) and the Spanish National Research Council (CSIC) in Seville (Spain). In 2003, he accepted a position at TUM. Prof. Schwab is a member of the BfR Committee for Genetically Modified Food and Feed.


Flavor is the sensory impression of a food and is determined mainly by the chemical senses of smell and taste. In plant derived food, a large fraction of the volatile compounds that may impart aroma (smell) are also present as non-volatile aroma glycosides. They have attracted much attention as antimicrobials and detergents but also as flavor precursors and taste modifiers. The glycosides are either extracted from plant materials or are synthesized by chemical and biocatalytic methods. Up to now, biotechnological production of aroma glycosides is based mainly on reversed hydrolysis performed by glycosidases or transglycosidases. However, these methods suffer from low yields and the excess of the starting materials.